Literature DB >> 12142628

Characterization of methadone overdose: clinical considerations and the scientific evidence.

Kim Wolff1.   

Abstract

Overdosing with methadone is a growing phenomenon in Britain and other countries due to the increase in prescription and the availability of this compound. Little is known of the circumstances surrounding methadone death due to some extent to the difficulty of defining drug-related death and also the difficulty of collecting clinical and biographical data in a predominantly illegal and marginal milieu. However, the evidence points to highest risk at night (to this end manifestations of its toxicity often go unrecognized) in those whose usual tolerance has been reduced and occurring some considerable time after ingestion. Further investigations are needed to elucidate fully the mechanism and spectrum of methadone overdose. Death from methadone is eminently preventable more so because of the long-term nature of the clinical sequelae. Indeed the key issue with methadone that sets it apart from other opioids is its potential for delayed toxicity. Consequently steps should be taken to disseminate the salient facts to all those who come into contact with the drug.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142628     DOI: 10.1097/00007691-200208000-00001

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  25 in total

Review 1.  Methadone for treatment of cancer pain.

Authors:  John Bryson; Anoo Tamber; Dori Seccareccia; Camilla Zimmermann
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

2.  Need and utility of a polyethylene glycol marker to ensure against urine falsification among heroin users.

Authors:  Jermaine D Jones; Jared J Atchison; Gabriela Madera; Verena E Metz; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2015-05-27       Impact factor: 4.492

3.  The source of methadone in overdose deaths in Western Virginia in 2004.

Authors:  Melissa B Weimer; P Todd Korthuis; George S Behonick; Martha J Wunsch
Journal:  J Addict Med       Date:  2011-09       Impact factor: 3.702

Review 4.  Methadone deaths: risk factors in pain and addicted populations.

Authors:  Vania Modesto-Lowe; Donna Brooks; Nancy Petry
Journal:  J Gen Intern Med       Date:  2010-01-20       Impact factor: 5.128

5.  Methadone-induced toxic leukoencephalopathy: MR imaging and MR proton spectroscopy findings.

Authors:  R A Salgado; P G Jorens; I Baar; P Cras; G Hans; P M Parizel
Journal:  AJNR Am J Neuroradiol       Date:  2009-11-05       Impact factor: 3.825

6.  The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia.

Authors:  Shelley R Salpeter; Jacob S Buckley; Eduardo Bruera
Journal:  J Palliat Med       Date:  2013-04-04       Impact factor: 2.947

Review 7.  Polydrug abuse: a review of opioid and benzodiazepine combination use.

Authors:  Jermaine D Jones; Shanthi Mogali; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-08-02       Impact factor: 4.492

8.  The relationship between self-reported substance use and psychiatric symptoms in low-threshold methadone maintenance treatment clients.

Authors:  Heather G Fulton; Sean P Barrett; Cindy Macisaac; Sherry H Stewart
Journal:  Harm Reduct J       Date:  2011-07-28

9.  Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds.

Authors:  Paul J Whelan; Kimberly Remski
Journal:  J Neurosci Rural Pract       Date:  2012-01

10.  Methodology for the Randomised Injecting Opioid Treatment Trial (RIOTT): evaluating injectable methadone and injectable heroin treatment versus optimised oral methadone treatment in the UK.

Authors:  Nicholas Lintzeris; John Strang; Nicola Metrebian; Sarah Byford; Christopher Hallam; Sally Lee; Deborah Zador
Journal:  Harm Reduct J       Date:  2006-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.